MedTrace Logo

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

NCT04371796 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-05-01

No results posted yet for this study

Summary

The aim of this study was to investigate the safety and efficacy of Sintilimab (IBI308) in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with stage II-IIIA NSCLC

Conditions

  • Lung Diseases
  • Neoplasms
  • Respiratory Tract Diseases
  • Thoracic Neoplasms
  • Non-small-cell Lung Cancer

Interventions

DRUG

Sintilimab injection

Sintilimab injection 200mg, 2cycles of treatment before surgery

Sponsors & Collaborators

Principal Investigators

  • Juan Li, MD · Sichuan Cancer Hospital and Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-10
Primary Completion
2021-06-30
Completion
2021-12-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04371796 on ClinicalTrials.gov